The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
Open accessAbstract
BACKGROUND & AIMS: We investigated the effects of the fatty acid-bile acid conjugate 3β-arachidyl-amido, 7α-12α-dihydroxy, 5β-cholan-24-oic acid (Aramchol; Trima Israel Pharmaceutical Products Ltd, Maabarot, Israel) in a phase 2 trial of patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We performed a randomized, double-blind, placebo-controlled trial of 60 patients with biopsy-confirmed NAFLD (6 with nonalcoholic steatohepatitis) at 10 centers in Israel. Patients were given Aramchol (100 or 300 mg) or placebo once daily for 3 months (n = 20/group). The main end point was the difference between groups in the change in liver fat content according to magnetic resonance spectroscopy. The secondary end points focused on the differences between groups in alterations of liver enzyme levels, levels of adiponectin, homeostasis model assessment scores, and endothelial function. RESULTS: No serious or drug-related adverse events were observed in the 58 patients who completed the study. Over 3 months, liver fat content decreased by 12.57% ± 22.14% in patients given 300 mg/day Aramchol, but increased by 6.39% ± 36.27% in the placebo group (P = .02 for the difference between groups, adjusted for age, sex, and body mass index). Liver fat content decreased in the 100-mg Aramchol group, by 2.89% ± 28.22%, but this change was nonsignificant (P = .35), indicating a dose-response relationship (P for trend = .01). Groups given Aramchol had nonsignificant improvements over time in endothelial function and levels of alanine aminotransferase and adiponectin, but homeostasis model assessment scores did not change. The appropriateness of a single daily dose was confirmed by pharmacokinetic analysis. CONCLUSIONS: Three months' administration of the fatty acid-bile acid conjugate Aramchol is safe, tolerable, and significantly reduces liver fat content in patients with NAFLD. The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease. ClinicalTrials.gov number: NCT01094158.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Gaggini, M., Morelli, M., Buzzigoli, E., DeFronzo, R., Bugianesi, E., & Gastaldelli, A. (2013) · Nutrients · doi:10.3390/nu5051544 · Cited by 822
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
Dixon, J. B., Bhathal, P. S., Hughes, N. R., & O'Brien, P. E. (2004) · Hepatology · doi:10.1002/hep.20251 · Cited by 727 · cited 1×
“However, liver fat reduction alone has been shown to reverse NASH in studies with effective weight reduction regimens(26) and in patients undergoing bariatric surgery.(25,27) A regression in NASH has been shown to accompany the decrease in LFC in patients treated with thiazolidinedione, despite the fact that the treat…”
BackgroundEndothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease†
Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., Zoli, M., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20781 · Cited by 629
Mathurin, P., Hollebecque, A., Arnalsteen, L., Buob, D., Leteurtre, E., Caiazzo, R., Pigeyre, M., Verkindt, H., Dharancy, S., Louvet, A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.052 · Cited by 483
Brevetti, G., Silvestro, A., Schiano, V., & Chiariello, M. (2003) · Circulation · doi:10.1161/01.cir.0000095273.92468.d9 · Cited by 482
Nobili, V., Manco, M., Devito, R., Di Ciommo, V., Comparcola, D., Sartorelli, M. R., Piemonte, F., Marcellini, M., & Angulo, P. (2008) · Hepatology · doi:10.1002/hep.22336 · Cited by 415
Dobrzyn, P., Dobrzyn, A., Miyazaki, M., Cohen, P., Asilmaz, E., Hardie, D. G., Friedman, J. M., & Ntambi, J. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401627101 · Cited by 393
Dufour, J., Oneta, C. M., Gonvers, J., Bihl, F., Cerny, A., Cereda, J., Zala, J., Helbling, B., Steuerwald, M., & Zimmermann, A. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.025 · Cited by 358
Schwimmer, J. B., Middleton, M. S., Deutsch, R., & Lavine, J. E. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02420.x · Cited by 243
Nonalcoholic fatty liver disease
Krawczyk, M., Bonfrate, L., & Portincasa, P. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.08.005 · Cited by 187
Stearoyl‐CoA desaturase as a new drug target for obesity treatment
Dobrzyn, A., & Ntambi, J. M. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00177.x · Cited by 174
Kang, G. H., Cruite, I., Shiehmorteza, M., Wolfson, T., Gamst, A. C., Hamilton, G., Bydder, M., Middleton, M. S., & Sirlin, C. B. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22701 · Cited by 158
Endothelial Dysfunction as an Early Sign of Atherosclerosis
Giannotti, G., & Landmesser, U. (2007) · Herz · doi:10.1007/s00059-007-3073-1 · Cited by 156
(2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.001 · Cited by 144
Review article: hepatic steatosis and insulin resistance
Lonardo, A., Lombardini, S., RICCHI, M., Scaglioni, F., & Loria, P. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02600.x · Cited by 110
MacDonald, M. L. E., Eck, M. V., Hildebrand, R. B., Wong, B. W., Bissada, N., Ruddle, P., Kontush, A., Hussein, H., Pouladi, M. A., Chapman, M. J., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.181099 · Cited by 108
Bell, L. N., Wang, J., Muralidharan, S. S., Chalasani, S., Fullenkamp, A. M., Wilson, L., Sanyal, A. J., Kowdley, K. V., Neuschwander‐Tetri, B. A., Brunt, E. M., et al. (2012) · Hepatology · doi:10.1002/hep.25805 · Cited by 107
Zhang, Z., Dales, N. A., & Winther, M. D. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401516c · Cited by 87
Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: a review
Fischbach, F., & Bruhn, H. (2008) · Liver International · doi:10.1111/j.1478-3231.2007.01647.x · Cited by 84
Lonardo, A., Bellentani, S., Ratziu, V., & Loria, P. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.19 · Cited by 68
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis
Mahady, S. E., Wong, G., Craig, J. C., & George, J. (2012) · Hepatology · doi:10.1002/hep.25887 · Cited by 51
Leikin-Frenkel, A. I., Gonen, A., Shaish, A., Goldiner, I., Leikin-Gobbi, D., Konikoff, F. M., Harats, D., & Gilat, T. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.09.001 · Cited by 49
Self-citationBariatric surgery for curing NASH in the morbidly obese?
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.026 · Cited by 47
Adiponectin: linking the metabolic syndrome to its cardiovascular consequences
Rabin, K. R., Kamari, Y., Avni, I., Grossman, E., & Sharabi, Y. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.3.465 · Cited by 47
Leikin-Frenkel, A. I., Goldiner, I., Leikin-Gobbi, D., Rosenberg, R. A., Bonen, H., Litvak, A., Bernheim, J., Konikoff, F. M., & Gilat, T. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282fc9743 · Cited by 33
Self-citationGoldiner, I., van der Velde, A. E., Vandenberghe, K., van Wijland, M. J. A., Halpern, Z., Gilat, T., Konikoff, F. M., Veldman, R. J., & Groen, A. K. (2006) · Biochemical Journal · doi:10.1042/bj20051694 · Cited by 29
Self-citationKonikoff, F. M., & Gilat, T. (2005) · Current Drug Targets - Immune Endocrine & Metabolic Disorders · doi:10.2174/1568008054064904 · Cited by 23
Self-citationPharmacologic Therapy for Nonalcoholic Fatty Liver Disease in Adults
Malinowski, S. S., Byrd, J. S., Bell, A. M., Wofford, M. R., & Riche, D. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1190 · Cited by 16
Bo-Abbas, Y. Y. (2002) · New England Journal of Medicine · doi:10.1056/nejm200206063462316 · Cited by 4
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Metadata
- Authors
- Safadi, R., Konikoff, F. M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., Oren, R., Safadi, R., Konikoff, F. M., Hershkovitz, A., Gilat, T., Halpern, M., Rosenthal-Galili, Z., Zuckerman, E., Abu-Mouch, S., Fich, A., Sikuler, E., Issachar, A., Assy, N., Baruch, Y., Lurie, Y., Graif, M., Stern, N., Yaron, M., Blank, A., Ben Bashat, D., Zelber-Sagi, S., Mahamid, M., Mizrahi, M., & Oren, R.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 12
- Issue
- 12
- Pages
- 2085-2091.e1
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2108347074
- Cited by
- 274
- References
- 34
- FWCI
- 15.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.